Literature DB >> 10235022

Direct anastomotic bypass for cerebrovascular moyamoya disease.

S Miyamoto1, I Nagata, N Hashimoto, H Kikuchi.   

Abstract

Therapeutic result and pitfalls in the surgical treatment of cerebrovascular moyamoya disease are evaluated. During the recent 15 years, 268 patients with moyamoya disease have been treated in our clinic. Among them, 238 patients showed ischemic symptoms. Superficial temporal artery to middle cerebral artery anastomoses combined with temporal muscle grafting (encephalo-myo-synangiosis) were performed for most of the cases. Complete remission and clinical improvement were obtained in 34.0% and 64.2% of the patients, respectively. Symptomatic aggravation due to ischemic complication followed the operation in five patients (1.9%). Normocapnic control during general anesthesia with sufficient hydration is essential to avoid perioperative ischemic complications. Omental graft was performed in 16 patients. In 13 patients, omental graft was performed for the progressing ischemia in the posterior cerebral artery or anterior cerebral artery distribution. In the other three patients, omental graft was used for marked brain atrophy.

Entities:  

Mesh:

Year:  1998        PMID: 10235022     DOI: 10.2176/nmc.38.suppl_294

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  3 in total

Review 1.  Revascularisation surgery for paediatric moyamoya: a review of the literature.

Authors:  Lai-Wah Eva Fung; Dominic Thompson; Vijeya Ganesan
Journal:  Childs Nerv Syst       Date:  2005-02-05       Impact factor: 1.475

2.  Endovascular stenting of an extracranial-intracranial saphenous vein high-flow bypass graft: Technical case report.

Authors:  Giuliano Maselli; Claudio De Tommasi; Alessandro Ricci; Massimo Gallucci; Renato J Galzio
Journal:  Surg Neurol Int       Date:  2011-04-19

Review 3.  Cognitive Dysfunction Survey of the Japanese Patients with Moyamoya Disease (COSMO-JAPAN Study): study protocol.

Authors:  Yasushi Takagi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-02-20       Impact factor: 1.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.